BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver injury. The spectrum of NAFLD is broad, extending from simple steatosis through nonalcoholic steatohepatitis (NASH). Insulin resistance has been found to increase the risk of NASH, and obesity, and decreased levels of adiponectin are important factors in determining the severity of insulin resistance. Recent evidence has indicated that hypoadiponectinemia is involved in hepatic steatosis and NASH. METHODS: To investigate whether hypoadiponectinemia causes hepatic steatosis in type 2 diabetes mellitus (DM) patients independently of visceral adipose tissue, we measured the plasma adiponectin concentration, hepatic fat content based on the liver-to-spleen ratio (L/S ratio) according to computed tomography (CT) attenuation values, and the amount of visceral adipose tissue and subcutaneous adipose tissue by CT in 248 type 2 DM patients. We also investigated the relationship between the serum level of adiponectin and hepatic fibrosis. RESULTS: Significant correlations were observed between the L/S ratios and aspartate aminotransferase, alanine aminotransferase, visceral adipose tissue, subcutaneous adipose tissue, and serum adiponectin values (r=0.300, p=0.0007), and there was a highly significant inverse correlation between the visceral adipose tissue values and the serum adiponectin levels (r=-0.327, p<0.0002). The subcutaneous adipose tissue values, however, were not correlated with the serum adiponectin levels. Multiple regression analysis was used to quantify the impact of measured variables on the L/S ratio. After adjustment for age, gender, and visceral adipose tissue, the serum adiponectin levels were still significantly correlated with the L/S ratios (p=0.0064). And there was a stepwise decrease in the serum adiponectin in parallel to the severity of hepatic fibrosis. CONCLUSIONS: Hypoadiponectinemia is concluded to be involved in the etiology of hepatic steatosis independently of visceral adipose tissue content, and is considered to be an important factor in the progression of fibrosis; further studies will be necessary to elucidate the exact physiological role of adiponectin and its contribution to the progression of NASH.
BACKGROUND:Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver injury. The spectrum of NAFLD is broad, extending from simple steatosis through nonalcoholic steatohepatitis (NASH). Insulin resistance has been found to increase the risk of NASH, and obesity, and decreased levels of adiponectin are important factors in determining the severity of insulin resistance. Recent evidence has indicated that hypoadiponectinemia is involved in hepatic steatosis and NASH. METHODS: To investigate whether hypoadiponectinemia causes hepatic steatosis in type 2 diabetes mellitus (DM) patients independently of visceral adipose tissue, we measured the plasma adiponectin concentration, hepatic fat content based on the liver-to-spleen ratio (L/S ratio) according to computed tomography (CT) attenuation values, and the amount of visceral adipose tissue and subcutaneous adipose tissue by CT in 248 type 2 DMpatients. We also investigated the relationship between the serum level of adiponectin and hepatic fibrosis. RESULTS: Significant correlations were observed between the L/S ratios and aspartate aminotransferase, alanine aminotransferase, visceral adipose tissue, subcutaneous adipose tissue, and serum adiponectin values (r=0.300, p=0.0007), and there was a highly significant inverse correlation between the visceral adipose tissue values and the serum adiponectin levels (r=-0.327, p<0.0002). The subcutaneous adipose tissue values, however, were not correlated with the serum adiponectin levels. Multiple regression analysis was used to quantify the impact of measured variables on the L/S ratio. After adjustment for age, gender, and visceral adipose tissue, the serum adiponectin levels were still significantly correlated with the L/S ratios (p=0.0064). And there was a stepwise decrease in the serum adiponectin in parallel to the severity of hepatic fibrosis. CONCLUSIONS:Hypoadiponectinemia is concluded to be involved in the etiology of hepatic steatosis independently of visceral adipose tissue content, and is considered to be an important factor in the progression of fibrosis; further studies will be necessary to elucidate the exact physiological role of adiponectin and its contribution to the progression of NASH.
Authors: Mingyan Zhou; Aimin Xu; Paul K H Tam; Karen S L Lam; Lawrence Chan; Ruby L C Hoo; Jing Liu; Kim H M Chow; Yu Wang Journal: Hepatology Date: 2008-10 Impact factor: 17.425
Authors: Shoba Shetty; Maria A Ramos-Roman; You-Ree Cho; Jonathan Brown; Jorge Plutzky; Eric S Muise; Jay D Horton; Philipp E Scherer; Elizabeth J Parks Journal: Endocrinology Date: 2011-11-01 Impact factor: 4.736
Authors: Marianna Argentou; Dina G Tiniakos; Menelaos Karanikolas; Maria Melachrinou; Maria G Makri; Christos Kittas; Fotis Kalfarentzos Journal: Obes Surg Date: 2009-07-15 Impact factor: 4.129
Authors: Aramesh Saremi; Matthew Allison; Dominic Ditomasso; Ling Ge; Robert Anderson; Tom E Moritz; William Duckworth; Carlos Abraira; Peter D Reaven Journal: Metabolism Date: 2009-10-21 Impact factor: 8.694
Authors: P Matafome; E Nunes; T Louro; C Amaral; J Crisóstomo; L Rodrigues; A R Moedas; P Monteiro; A Cipriano; R Seiça Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2008-10-21 Impact factor: 3.000
Authors: William P Cawthorn; Erica L Scheller; Sebastian D Parlee; H An Pham; Brian S Learman; Catherine M H Redshaw; Richard J Sulston; Aaron A Burr; Arun K Das; Becky R Simon; Hiroyuki Mori; Adam J Bree; Benjamin Schell; Venkatesh Krishnan; Ormond A MacDougald Journal: Endocrinology Date: 2015-12-22 Impact factor: 4.736
Authors: Zhen Yang; Xuanchun Wang; Jie Wen; Zi Ye; Qin Li; Min He; Bin Lu; Charlotte Ling; Songhua Wu; Renming Hu Journal: Arch Med Sci Date: 2011-09-02 Impact factor: 3.318